Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Recruiting 4Not yet recruiting 4Completed 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 3Pleural Effusion, Malignant 1NSCLC 1Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × aflutinib × 90 days × Clear all
NCT07622186 2026-06-03

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
150 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07622706 2026-06-03

Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma

Peking University Cancer Hospital & Institute

Phase 2 Not yet recruiting
60 enrolled
Thoracic

NSCLC

NCT07517640 2026-04-08

Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Not yet recruiting
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07482605 2026-03-20

Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion

Jiangmen Central Hospital

Phase 2 Not yet recruiting
63 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡